Becton Dickinson and Company (BDX) – Growth through Innovation

Becton Dickinson and Company (BDX) (Q2FY23)

Introduction

Becton Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.

The company’s BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Its BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.

The company’s BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products.

Highlights

The company’s medical segment and interventional business experienced growth of 9.6% and 6.8%, respectively, the life sciences revenue declined by 14.2% due to a decrease in COVID-only diagnostic testing revenues.

BDX revenues was $4.821bn increased 1.5% in Q2FY23 from Q2FY22. The revenue decreased to $9.41bn in 1HFY23 compared to $9.47bn in 1HFY22.

Stock Performance

Becton Dickinson’s stock price showed a volatile trend in past 3-months period. It increased by 7.7% during the period. The stock price showed a volatile trend in past 3-months period. It increased by 7.7% during the period.

In the past 3 years, the stock has given returns of 12.22%. BDX has a 50-day moving Avg. and 200-day moving Avg. of $253.72 and $244.53, respectively.

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– CrispIdea Segment Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages: 36

To download the previous quarter’s equity report CLICK HERE

Follow our LinkedIn page for more updates